Nektar Therapeutics announced positive results from the SUMMIT-07 Phase 3 study of NKTR-181 for the treatment of moderate-to-severe chronic pain.
Lea Eslava-Kim, PharmDDrug Information Specialist https://www.clinicalpainadvisor.com
Lea Eslava-Kim, PharmD, is a Drug Information Specialist for MPR. She received her doctorate in pharmacy from the Ernest Mario School of Pharmacy, Rutgers University and completed her pharmacy residency at Clara Maass Medical Center. She is a licensed pharmacist.